On The Pen GLP-1 News4 Jun 2024

On The Pen: The Weekly Dose 6.4.24

Send a text

https://ro.co/weight-loss/supply-tracker
https://www.youtube.com/watch?v=mL_krAas70k

Novo Nordisk Advertising:

Novo Nordisk launches new advertising campaign "The Power of Wegovy"
This advertisement includes the new indication for reduction of cardiovascular risk
For 2023, the #5 advertising spend for a drug was Rybelsus at $191 million. The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic went to online video platforms (i.e. social media like youtube)
Link: https://www.youtube.com/watch?v=dhretLXYkZ4

Structure Therapeutics GSBR-1290

GSBR-1290 is a small molecule GLP-1 pill
In a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipron
At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placebo
Also developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small molecules
Link (Madison Muller): https://www.bloomberg.com/news/articles/2024-06-03/structure-reports-early-oral-weight-loss-drug-data-adding-allure

Elon musk tweet:

Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It’s not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changer
This tweet has currently been seen 325,500 times

Shanghai Stem Cell Type 2 Diabetes Treatment
https://www.scmp.com/news/china/science/article/3263878/chinese-scientists-report-world-first-they-cure-patients-diabetes-cell-therapy

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv

📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(198)

Compound GLP-1 Poll STUNS THE INTERNET!

What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with the drug itself, and e...

8 Jul 15min

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Jun 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ⁠ to break down the molecules, clinica...

16 Jun 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Jun 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Jun 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Jun 20min